Pfizer Increases 2006 Earnings Guidance, Sees Robust Late-Stage Pipeline

THURSDAY, Nov. 30 (HealthDay News) -- A U.S. government advisory panel's recommendation to allow Celebrex to be used for children with juvenile rheumatoid arthritis isn't likely to change the treatment landscape dramatically.

A PAINFUL MIGRAINE can make anyone feel desperate. Even a Desperate Housewife. "My first one happened when I was 14," recalls Marcia Cross, who plays Bree Van De Kamp on ABC's "Desperate Housewives."

Medical advances are making it possible for war fighters to survive injuries that even a few years ago surely would have killed them. But they often end up living in chronic pain.

GROTON, Conn., Nov. 30 /PRNewswire-FirstCall/

(AP) CUPERTINO, Calif. Shares of Durect Corp. soared Thursday morning after the specialty drug maker signed a development deal worth up to $202 million with Danish drugmaker Nycomed, and said an early stage clinical trial showed one of its abuse-resistant painkillers was safe and well-tolerated.

Pfizer's CEO raised the No. 1 drugmaker's earnings guidance for 2006, and executives said the company plans to triple its late-stage drug pipeline by 2009.

Pfizer's CEO raised the No. 1 drugmaker's earnings guidance for 2006, and executives said the company plans to triple its late-stage drug pipeline by 2009.

Radiologists are using an unusual approach, hypnosis, to ease patient pain and anxiety during breast biopsy procedures. A new study from Beth Israel Deaconess Medical Center and Harvard Medical School in Boston found that women who were guided into a state of hypnotic relaxation during biopsy experienced less pain and anxiety during the procedure. The study was presented at the annual meeting of

Pfizer Inc. should get U.S. approval to market its Celebrex arthritis-pain pill for use in children because the benefits outweigh the risks, a Food and Drug Administration advisory panel said Wednesday.